Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma
- PMID: 37034513
- PMCID: PMC10074319
- DOI: 10.5114/aoms/112525
Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma
Abstract
Introduction: The prognosis of malignant pleural mesothelioma (MPM) is poor, with a limited survival time. In this study, we aimed to examine expression levels of genes selected from relevant literature and to utilize in silico methods to determine genes whose expression could reflect the prognosis of patients with MPM by ex-vivo validation experiments.
Material and methods: The study group consisted of 54 MPM patients treated with chemotherapy. Expression of 6 genes - midkine (MDK), syndecan-1 (SDC1), hyaluronan synthase-2 (HAS2), sestrin-1 (SESN1), laminin subunit alpha-4 (LAMA4), and fibulin-3 (FBLN3) - was examined by qPCR in tumor tissues. Sestrin-1 and LAMA4 were identified using an in house R-based script: Unsupervised Survival Analysis Tool. Midkine, SDC1, HAS2, and FBLN3 were selected from current literature. We used two housekeeping genes, i.e. glucose-6-phosphate dehydrogenase and TATA-box binding protein, as controls.
Results: Of the patients, 43 (79.6%) had epithelioid mesothelioma. The median survival for all patients was 10 (±1.2 SE) months (95% CI: 7.7-12.3). In multivariate analyses, MDK (p = 0.007), HAS2 (p = 0.008) and SESN1 (p = 0.014) expression levels were related to survival time in the whole group. In epithelioid type MPM patients, MDK (p = 0.014), FBLN3 (p = 0.029), HAS2 (p = 0.014) and SESN1 (p = 0.045) expression was related to survival time in multivariate analyses.
Conclusions: High HAS2 and SESN1 expressions and low MDK are potential biomarkers of good prognosis in MPM. High HAS2 and SESN1 expression and low MDK and FBLN3 can also be utilized as biomarkers of good prognosis for epithelioid MPM. Those results should be further investigated in sera, plasma, and pleural effusions.
Keywords: fibulin-3; hyaluronan synthase-2; laminin subunit alpha-4; mesothelioma; midkine; prognosis; sestrin-1; syndecan-1.
Copyright: © 2021 Termedia & Banach.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11. Br J Cancer. 2015. PMID: 26263483 Free PMC article.
-
Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.Anticancer Res. 2017 Mar;37(3):1387-1391. doi: 10.21873/anticanres.11460. Anticancer Res. 2017. PMID: 28314308
-
Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers.Cancer Biomark. 2023;38(1):111-120. doi: 10.3233/CBM-220436. Cancer Biomark. 2023. PMID: 37545218
-
The established and future biomarkers of malignant pleural mesothelioma.Cancer Treat Rev. 2015 Jun;41(6):486-95. doi: 10.1016/j.ctrv.2015.05.001. Epub 2015 May 8. Cancer Treat Rev. 2015. PMID: 25979846 Review.
-
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.Lung Cancer. 2020 Aug;146:318-326. doi: 10.1016/j.lungcan.2020.06.024. Epub 2020 Jun 21. Lung Cancer. 2020. PMID: 32622302
Cited by
-
Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis.J Transl Med. 2024 Aug 30;22(1):807. doi: 10.1186/s12967-024-05606-9. J Transl Med. 2024. PMID: 39215354 Free PMC article.
References
-
- Metintas M, Ozdemir N, Hillerdal G, et al. . Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 1999; 93: 349-55. - PubMed
-
- Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8. - PubMed
-
- Metintas M, Metintas S, Ucgun I, et al. . Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 2001; 95: 829-35. - PubMed
-
- Ruffie PA. Pleural mesothelioma. Curr Opin Oncol 1991; 3: 328-34. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous